Abstract
The expression of ZNRD1 in esophageal cancer was first investigated by immunohistochemical analysis, RT-PCR and real-time PCR. The ZNRD1 antibody produced a consistently cytoplasmic staining pattern in all epithelial cells. The expression of ZNRD1 was statistically correlated with differentiation, depth of invasion, lymph node metastasis, pathological stage, lymphatic invasion, and vascular invasion. The survival rates of patients with ZNRD1-negative tumors tended to be statistically lower than those with ZNRD1-positive tumors. ZNRD1 expression was also confirmed to be down-regulated in esophageal cancer tissues compared to adjacent non-neoplastic tissues. The results showed that ZNRD1 might play an important role in esophageal carcinogenesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hong L, Wang J, Zhao Y, Han Z, Zhou X, Guo W (2007) DARPP-32 mediates multidrug resistance of gastric cancer through regulation of P-gp and ZNRD1. Cancer Invest 25(8):699–705. doi:10.1080/07357900701566304
Hong L, Chen Z, Zhang X, Xia L, Han Z, Lu Y (2006) Zinc ribbon domain containing 1 protein: modulator of multidrug resistance, tumorigenesis and cell cycle. Exp Oncol 28(4):258–262
Hong L, Qiao T, Han Y, Han S, Zhang X, Lin T (2006) ZNRD1 mediates resistance of gastric cancer cells to methotrexate by regulation of IMPDH2 and Bcl-2. Biochem Cell Biol 84(2):199–206. doi:10.1139/o05-173
Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M (2000) Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 232:225–232. doi:10.1097/00000658-200008000-00013
Tabernero J, Macarulla T, Ramos FJ, Baselga J (2005) Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 16(11):1740–1748. doi:10.1093/annonc/mdi355
Hong L, Piao Y, Han Y, Wang J, Zhang X, Du Y (2005) Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Mol Cancer Ther 4(12):1936–1942. doi:10.1158/1535-7163.MCT-05-0182
Kuwano H, Nakajima M, Miyazaki T, Kato H (2003) Distinctive clinicopathological characteristics in esophageal squamous cell carcinoma. Ann Thorac Cardiovasc Surg 9(1):6–13
Hong L, Han Y, Han Y, Zhao Y, Zhang X, Qiao T (2007) Mechanisms of growth arrest by zinc ribbon domain-containing 1 (ZNRD1) in gastric cancer cells. Carcinogenesis 28(8):1622–1628. doi:10.1093/carcin/bgm064
Qian X, Jeon C, Yoon H, Agarwal K, Weiss MA (1993) Structure of a new nucleic-acid-binding motif in eukaryotic transcriptional elongation factor TFIIS. Nature 365:277–279. doi:10.1038/365277a0
Hong L, Zhao Y, Wang J, Han Y, Guo W, Jin H (2008) Reversal of multidrug resistance of adriamycin-resistant gastric adenocarcinoma cells through the up-regulation of DARPP-32. Dig Dis Sci 53(1):101–107. doi:10.1007/s10620-007-9829-x
Hong L, Han Y, Shi R, Shao X, Sun L, Zhang Y (2005) ZNRD1 gene suppresses cell proliferation through cell cycle arrest in G1 phase. Cancer Biol Ther 4(1):60–64. doi:10.1158/1535-7163.MCT-05-0182
Hong L, Ning X, Shi Y, Shen H, Zhang Y, Lan M (2004) Reversal of multidrug resistance of gastric cancer cells by down-regulation of ZNRD1 with ZNRD1 siRNA. Br J Biomed Sci 61(4):206–210
Hong L, Wang J, Han Y, Zhao Y, Gao J, Wang J (2007) Reversal of multidrug resistance of vincristine-resistant gastric adenocarcinoma cells through up-regulation of DARPP-32. Cell Biol Int 31(9):1010–1015. doi:10.1016/j.cellbi.2007.03.020
Hong L, Zhang Y, Liu N, Liu C, Zhi M, Pan Y (2004) Suppression of the cell proliferation in stomach cancer cells by the ZNRD1 gene. Biochem Biophys Res Commun 321(3):611–616. doi:10.1016/j.bbrc.2004.07.007
Hong L, Zhang Y, Han S, Wang J, Shi Y, Pan Y (2004) Preparation and characterization of a novel monoclonal antibody specific to human ZNRD1 protein. Hybrid Hybridomics 23(1):65–68. doi:10.1089/153685904322772042
Igaki H, Kato H, Tachimori Y, Nakanishi Y (2003) Prognostic evaluation of patients with clinical T1 and T2 squamous cell carcinomas of the thoracic esophagus after 3-field lymph node dissection. Surgery 133(4):368–374. doi:10.1067/msy.2003.76
Ogata Y, Fujita H, Yamana H, Sueyoshi S, Shirouzu K (2003) Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study. World J Surg 27(5):584–589. doi:10.1007/s00268-003-6866-2
Brucher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H (2006) The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 106(10):2119–2127. doi:10.1002/cncr.21850
Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T (2003) Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 238(2):197–202
Acknowledgments
This study was supported in part by grants from the Chinese Post-doctoral Foundation (20070410374) and Xijing Zhutui Project (Xjzt07z04). We thank Mr. Zenpeng Li (Department of Pathology, Institute of Surgery Research, Daping Hospital, Chongqing, China) for his excellent technical assistance and Mr. Yunming Li (Department of Health Statistics, The Fourth Military Medical University, Xi’an, P.R. China) for his statistical analysis assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
Yunping Zhao and Liu Hong contributed equally to this study.
An erratum to this article is available at http://dx.doi.org/10.1007/s10620-010-1437-5.
Rights and permissions
About this article
Cite this article
Zhao, Y., Hong, L., Wang, R. et al. Expression and Prognostic Value of ZNRD1 in Esophageal Squamous Cell Carcinoma. Dig Dis Sci 54, 586–592 (2009). https://doi.org/10.1007/s10620-008-0380-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-008-0380-1